Resource Summary Report

Generated by dkNET on Aug 5, 2026

Anti-phospho-Histone H2A.X (Ser139) Antibody, clone JBW301

RRID:AB_309864
Type: Antibody

Proper Citation

Sigma-Aldrich Cat# 05-636, RRID:AB_309864

Antibody Information

URL: http://antibodyregistry.org/AB_309864

Proper Citation: Sigma-Aldrich Cat# 05-636, RRID:AB_309864

Target Antigen: phospho-Histone H2A.X (Ser139)

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: ChIP, immunocytochemistry, immunofluorescence, immunohistochemistry, western blot

Antibody Name: Anti-phospho-Histone H2A.X (Ser139) Antibody, clone JBW301

Description: This monoclonal targets phospho-Histone H2A.X (Ser139)

Target Organism: vertebrates

Clone ID: JBW301

Antibody ID: AB_309864

Vendor: Sigma-Aldrich

Catalog Number: 05-636

Record Creation Time: 20250820T012758+0000

Record Last Update: 20250820T110022+0000

Ratings and Alerts

No rating or validation information has been found for Anti-phospho-Histone H2A.X (Ser139) Antibody, clone JBW301.

No alerts have been found for Anti-phospho-Histone H2A.X (Ser139) Antibody, clone JBW301.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 485 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Patel UA, et al. (2026) CRISPR Screen Identifies HDAC3 as a Novel Radiosensitizing Target in Small Cell Lung Cancer. Molecular cancer therapeutics, 25(1), 183.

Safari M, et al. (2026) Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic ductal adenocarcinoma. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 84, 101312.

Ma Y, et al. (2026) Exploiting the polypharmacology of alectinib for synergistic RNA splicing disruption with RBM39 degraders. Cell reports, 45(1), 116784.

Pan T, et al. (2026) Balanced DNA-to-cytoplasm ratio at the 2-cell stage is critical for mouse preimplantation development. iScience, 29(1), 114416.

Okraine YV, et al. (2025) Versatile enhancement of the killing potential of anti-cancer agents achieved by peptide mimetics of the PCNA interface towards specialized DNA polymerases. Cell death & disease, 16(1), 503.

Dufourd J, et al. (2025) TELS1 stabilizes t-loops independently of TRF2 and controls telomere length in pluripotent cells. Cell reports, 44(9), 116260.

Lee S, et al. (2025) Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells. Cancer research, 85(15), 2890.

Galloy M, et al. (2025) Ubiquitination of the histone variant mH2A1.2 prevents toxic RAD18 accumulation at a subset of genomic loci upon replication stress. Molecular cell, 85(16), 3023.

Mennerich D, et al. (2025) The E3 ubiquitin ligase DTX3L and the deubiquitinase USP28 fine-tune DNA repair through mutual regulation of their protein levels. iScience, 28(8), 112990.

Dreute J, et al. (2025) Synergistic targeting of cancer cells through simultaneous inhibition of key metabolic enzymes. Cell death and differentiation.

Pai Bellare G, et al. (2025) Targeting Replication Fork Processing Synergizes with PARP Inhibition to Potentiate Lethality in Homologous Recombination Proficient Ovarian Cancers. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 12(18), e2410718.

Bradley J, et al. (2025) A secretome screen in primary human lung fibroblasts identifies FGF9 as a novel regulator of cellular senescence. SLAS discovery : advancing life sciences R & D, 32, 100223.

Flor AC, et al. (2025) Noncanonical inhibition of topoisomerase II alpha by oxidative stress metabolites. Redox biology, 80, 103504.

Lu S, et al. (2025) Targeting Monounsaturated Fatty Acid Metabolism for Radiosensitization of KRAS Mutant 3D Lung Cancer Models. Molecular cancer therapeutics, 24(6), 920.

Le Bozec B, et al. (2025) Circadian PERIOD proteins regulate TC-DSB repair through anchoring to the nuclear envelope. Molecular cell, 85(24), 4492.

Huang M, et al. (2025) Stra8 links neuronal activity to inhibitory circuit protection in the adult mouse brain. Cell reports, 44(11), 116513.

Nam JK, et al. (2025) Combined HIF-1? blockade and CHIR99021 treatment reverses pulmonary fibrosis via modulation endothelial-to-mesenchymal transition. iScience, 28(12), 114028.

Hofstad M, et al. (2025) Dual inhibition of ATR and DNA-PKcs radiosensitizes ATM-mutant prostate cancer. Oncogene, 44(22), 1746.

Cheng YY, et al. (2025) Loss of Predicted Cell Adhesion Molecule MPZL3 Promotes EMT in Ovarian Cancer. Cancer research communications, 5(7), 1180.

Roca MS, et al. (2025) Valproic acid improves the efficacy of oxaliplatin/fluoropyrimidine-based chemotherapy by targeting cancer stem cell via ?-Catenin modulation in colorectal cancer. Cell death & disease, 16(1), 583.